Prevalence and variability of depressive symptoms in Europe: update using representative data from the second and third waves of the European Health Interview Survey (EHIS-2 and EHIS-3)
Prevalence and variability of depressive symptoms in Europe: update using representative data from the second and third waves of the European Health Interview Survey (EHIS-2 and EHIS-3)
复制标题
DOI：
10.1016/s2468-2667(23)00220-7
复制
发表时间：
2023-11-01
影响因子：
50
通讯作者：
Alonso，Jordi
中科院分区：
文献类型：
--
作者：
Arias-de la Torre，Jorge;Vilagut，Gemma;Alonso，Jordi
评估临床相关抑郁症状的患病率及其可能的变化，国家和随着时间的推移可能是一个宝贵的资源，为制定公共卫生政策和预防资源，以减少心理健康负担。我们的目的是评估2018- 2020年欧洲临床相关抑郁症状点患病率的跨国差异，并评估2013-15年和2018- 2020年之间国家之间和时间上的点患病率差异。来自第二和第三波欧洲健康访谈调查参与者的数据使用了来自30个欧洲国家的EHIS-2（2013年至2015年）和EHIS-3（2018年至2020年）（n=542 580）。在总样本中，283692名属于EHIS-3的参与者被纳入研究（52.4%女性和47.5%男性）。 EHIS-3中的无应答率按国家分列，从12%到78%不等。临床相关抑郁症状的点患病率采用患者健康问卷的8项版本的10分或更高的截止评分进行评估。获得了粗患病率和调整后的患病率（aPR），以评估国家之间以及国家内部随时间推移的患病率差异。（95% CI 6.34 - 6.73），各国范围从希腊的1.85%（1.53 - 2.17）到瑞典的10.72%（10.04 - 11.40）。与其他欧洲国家相比，aPR最低的国家是希腊、塞尔维亚和塞浦路斯，aPR最高的国家是比利时、斯洛文尼亚和克罗地亚。观察到EHIS-2和EHIS-3之间的患病率小幅但显著增加（aPR 1·11 [1·07-1·14]）。观察到国家内点患病率随时间变化很大，aPR为0.63（0·54-0·74）匈牙利至1·88（1·53-2·31）在斯洛文尼亚。解释这项研究，基于大型和代表性的数据集和一个有效和可靠的筛选工具，用于评估抑郁症，表明2013年至2020年欧洲临床相关抑郁症状的点患病率保持相对稳定，各国之间存在很大差异。这些发现可以被认为是监测欧洲临床相关抑郁症状患病率的基线，并可以为国家和欧洲抑郁症预防策略的制定提供信息。
BackgroundAssessing the prevalence of clinically relevant depressive symptoms and their possible variation by country and over time could be a valuable resource to inform the development of public health policies and preventive resources to reduce mental health burden. We aimed to assess cross-national differences in the point prevalence of clinically relevant depressive symptoms in Europe in 2018–20, and to evaluate point prevalence differences between countries and over time between 2013–15 and 2018–20.MethodsIn this population-based study, data from participants in the second and third waves of the European Health Interview Survey (EHIS-2 from 2013 to 2015 and EHIS-3 from 2018 to 2020) from 30 European countries were used (n=542 580). From the total sample, 283 692 participants belonging to EHIS-3 were included in the study (52·4% women and 47·5% men). The non-response in EHIS-3 ranged by country, from 12% to 78%. Point prevalence of clinically relevant depressive symptoms was evaluated using a cutoff score of 10 or more for the 8-item version of the Patient Health Questionnaire. Crude prevalence ratios and adjusted prevalence ratios (aPRs) were obtained to assess differences in the prevalence between countries and over time within countries.FindingsThe point prevalence of clinically relevant depressive symptoms in Europe in 2018–20 was 6·54% (95% CI 6·34–6·73), ranging across countries from 1·85% (1·53–2·17) in Greece to 10·72% (10·04–11·40) in Sweden. Compared with the other European countries, those with the lowest aPRs were Greece, Serbia, and Cyprus and those with the highest aPRs were Belgium, Slovenia, and Croatia. A small but significant increase in the prevalence between EHIS-2 and EHIS-3 was observed (aPR 1·11 [1·07–1·14]). A wide variability over time in the point prevalence within countries was observed, ranging from an aPR of 0·63 (0·54–0·74) in Hungary to 1·88 (1·53–2·31) in Slovenia.InterpretationThis study, based on large and representative datasets and a valid and reliable screening tool for the assessment of depression, indicates that the point prevalence of clinically relevant depressive symptoms in Europe from 2013 to 2020 remains relatively stable, with wide variability between countries. These findings could be considered a baseline for monitoring the prevalence of clinically relevant depressive symptoms in Europe, and could inform policy for the development of preventive strategies for depression both at a country and European level.FundingCenter for Biomedical Research in Epidemiology and Public Health Network and AGAUR.